Advertisement

Tissue Engineering and Regenerative Medicine

, Volume 15, Issue 4, pp 467–475 | Cite as

Positive Effects of Bisphosphonates on Osteogenic Differentiation in Patient-Derived Mesenchymal Stem Cells for the Treatment of Osteoporosis

  • Misun Cha
  • Kyung Mee Lee
  • Jae Hyup Lee
Original Article
  • 36 Downloads

Abstract

BACKGROUND:

Recent evidence from in vitro and in vivo studies indicates that bisphosphonates may promote osteoblastic bone formation and potently inhibit osteoclast activity. However, little is known about the potential effect of bisphosphonates on the recruitment of osteoblastic precursors from patient-derived bone marrow stromal cells due to difficulties in accessing human bone marrow from healthy and disease subjects.

METHODS:

In this study, we evaluated the potential of using FDA-approved and clinically utilized bisphosphonates such as alendronate, ibandronate, and zoledronate to enhance the development of bone forming osteoblasts from osteoporosis patient- and healthy-person derived hBMSCs (op-MSCs and hp-MSCs, respectively). hBMSCs were obtained from postmenopausal women without endocrine diseases or receiving hormone replacement therapy. Cells were treated with or without a bisphosphonate (alendronate, ibandronate, and zoledronate) and analyzed over 21 days of culture.

RESULTS:

hBMSC from osteoporosis-patient with bisphosphonates treatment demonstrated a significant increase in Alizarin red staining after 7 days compared to that from healthy-person. Calcium contents and alkaline phosphatase (ALP) enzyme activity also demonstrated an increased propensity in hMSCs from osteoporosis-patient compared to those from healthy-person, although there were inter-individual variations. Gene expression levels varied among different donors. There were no significant differences in the effect on the osteoblastic differentiation of hBMSCs among alendronate, ibandronate, and zoledronate. Statistical significance in the osteoblastic differentiation of hBMSCs between the positive control group cultured in osteogenic medium alone and groups cultured in osteogenic medium supplemented with bisphosphonate was not shown either. These results might be due to various cell types of hBMSCs from individual clinical patients and concentrations of bisphosphonate used.

CONCLUSION:

Our study using a clinically relevant in vitro model suggests that bisphosphonate treatment is more effective for patients with osteoporosis than its preventive effect for healthy person. In addition, patient-specific responses to bisphosphonates should be considered rather than bisphosphonate type prior to prescription. Further investigations are needed to determine how bisphosphonates influence hBMSCs function to mediate bone quality and turnover in osteoporotic patients. Such studies can generate novel approaches to treat age-related osteoporotic bone loss.

Keywords

Osteoporosis Bisphosphonates Mesenchymal stem cell Osteoblast 

Notes

Acknowledgement

This work was supported by Mid-career Researcher Program through NRF grant funded by the Korea government (MSIP) (2016R1A2B3015048).

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

Ethical statement

Institutional review board approval and patient consenting was obtained for this study (IRB No. 06-2010-142).

Supplementary material

13770_2018_127_MOESM1_ESM.doc (49 kb)
Supplementary material 1 (DOC 49 kb)

References

  1. 1.
    Zaidi M. Skeletal remodeling in health and disease. Nat Med. 2007;13:791–801.CrossRefPubMedGoogle Scholar
  2. 2.
    Pittenger MF, Mackay AM, Beck SC, Jaiswal RK, Douglas R, Mosca JD, et al. Multilineage potential of adult human mesenchymal stem cells. Science. 1999;284:143–7.CrossRefPubMedGoogle Scholar
  3. 3.
    Sethe S, Scutt A, Stolzing A. Aging of mesenchymal stem cells. Ageing Res Rev. 2006;5:91–116.CrossRefPubMedGoogle Scholar
  4. 4.
    Brack AS, Rando TA. Intrinsic changes and extrinsic influences of myogenic stem cell function during aging. Stem Cell Rev. 2007;3:226–37.CrossRefPubMedGoogle Scholar
  5. 5.
    Muschler GF, Nitto H, Boehm CA, Easley KA. Age- and gender-related changes in the cellularity of human bone marrow and the prevalence of osteoblastic progenitors. J Orthop Res. 2001;19:117–25.CrossRefPubMedGoogle Scholar
  6. 6.
    Rachner TD, Khosla S, Hofbauer LC. Osteoporosis: now and the future. Lancet. 2011;377:1276–87.CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Li B, Ling Chau JF, Wang X, Leong WF. Bisphosphonates, specific inhibitors of osteoclast function and a class of drugs for osteoporosis therapy. J Cell Biochem. 2011;112:1229–42.CrossRefPubMedGoogle Scholar
  8. 8.
    Holder KK, Kerley SS. Alendronate for fracture prevention in postmenopause. Am Fam Physician. 2008;78:579–81.PubMedGoogle Scholar
  9. 9.
    Ohtori S, Orita S, Yamauchi K, Eguchi Y, Aoki Y, Nakamura J, et al. Does discontinuing teriparatide treatment and replacing it with bisphosphonate maintain the volume of the bone fusion mass after lumbar posterolateral fusion in women with postmenopausal osteoporosis? Asian Spine J. 2017;11:272–7.CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Park YS, Kim HS, Baek SW, Kong DY, Ryu JA. The effect of zoledronic acid on the volume of the fusion-mass in lumbar spinal fusion. Clin Orthop Surg. 2013;5:292–7.CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Seo JB, Yoo JS, Ryu JW, Yu KW. Influence of early bisphosphonate administration for fracture healing in patients with osteoporotic proximal humerus fractures. Clin Orthop Surg. 2016;8:437–43.CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Shoji KE, Earp BE, Rozental TD. The effect of bisphosphonates on the clinical and radiographic outcomes of distal radius fractures in women. J Hand Surg Am. 2018;43:115–22.CrossRefPubMedGoogle Scholar
  13. 13.
    Stone MA, Jakoi AM, Iorio JA, Pham MH, Patel NN, Hsieh PC, et al. Bisphosphonate’s and intermittent parathyroid hormone’s effect on human spinal fusion: a systematic review of the literature. Asian Spine J. 2017;11:484–93.CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Viereck V, Emons G, Lauck V, Frosch KH, Blaschke S, Gründker C, et al. Bisphosphonates pamidronate and zoledronic acid stimulate osteoprotegerin production by primary human osteoblasts. Biochem Biophys Res Commun. 2002;291:680–6.CrossRefPubMedGoogle Scholar
  15. 15.
    Reinholz GG, Getz B, Pederson L, Sanders ES, Subramaniam M, Ingle JN, et al. Bisphosphonates directly regulate cell proliferation, differentiation, and gene expression in human osteoblasts. Cancer Res. 2000;60:6001–7.PubMedGoogle Scholar
  16. 16.
    Plotkin LI, Weinstein RS, Parfitt AM, Roberson PK, Manolagas SC, Bellido T. Prevention of osteocyte and osteoblast apoptosis by bisphosphonates and calcitonin. J Clin Invest. 1999;104:1363–74.CrossRefPubMedGoogle Scholar
  17. 17.
    Klein BY, Ben-Bassat H, Breuer E, Solomon V, Golomb G. Structurally different bisphosphonates exert opposing effects on alkaline phosphatase and mineralization in marrow osteoprogenitors. J Cell Biochem. 1998;68:186–94.CrossRefPubMedGoogle Scholar
  18. 18.
    Malavasi M, Louro R, Barros MB, Teixeira LN, Peruzzo DC, Joly JC, et al. Effects of risedronate on osteoblastic cell cultures. Arch Oral Biol. 2016;68:43–7.CrossRefPubMedGoogle Scholar
  19. 19.
    Zara S, De Colli M, di Giacomo V, Zizzari VL, Di Nisio C, Di Tore U, et al. Zoledronic acid at subtoxic dose extends osteoblastic stage span of primary human osteoblasts. Clin Oral Investig. 2015;19:601–11.CrossRefPubMedGoogle Scholar
  20. 20.
    Casado-Díaz A, Santiago-Mora R, Dorado G, Quesada-Gómez JM. Risedronate positively affects osteogenic differentiation of human mesenchymal stromal cells. Arch Med Res. 2013;44:325–34.CrossRefPubMedGoogle Scholar
  21. 21.
    Benisch P, Schilling T, Klein-Hitpass L, Frey SP, Seefried L, Raaijmakers N, et al. The transcriptional profile of mesenchymal stem cell populations in primary osteoporosis is distinct and shows overexpression of osteogenic inhibitors. PLoS One. 2012;7:e45142.CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    Corrado A, Cantatore FP, Grano M, Colucci S. Neridronate and human osteoblasts in normal, osteoporotic and osteoarthritic subjects. Clin Rheumatol. 2005;24:527–34.CrossRefPubMedGoogle Scholar
  23. 23.
    Maruotti N, Corrado A, Neve A, Cantatore FP. Bisphosphonates: effects on osteoblast. Eur J Clin Pharmacol. 2012;68:1013–8.CrossRefPubMedGoogle Scholar
  24. 24.
    Lee JH, Baek HR, Lee KM, Zheng GB, Shin SJ, Jin YZ. The inhibitory effect of zoledronate on early-stage osteoinduction by recombinant human bone morphogenetic protein 2 in an osteoporosis model. Growth Factors. 2015;33:220–8.CrossRefPubMedGoogle Scholar
  25. 25.
    Kim HK, Kim JH, Abbas AA, Yoon TR. Alendronate enhances osteogenic differentiation of bone marrow stromal cells: a preliminary study. Clin Orthop Relat Res. 2009;467:3121–8.CrossRefPubMedGoogle Scholar
  26. 26.
    Orriss IR, Key ML, Colston KW, Arnett TR. Inhibition of osteoblast function in vitro by aminobisphosphonates. J Cell Biochem. 2009;106:109–18.CrossRefPubMedGoogle Scholar
  27. 27.
    Pozzi S, Vallet S, Mukherjee S, Cirstea D, Vaghela N, Santo L, et al. High-dose zoledronic acid impacts bone remodeling with effects on osteoblastic lineage and bone mechanical properties. Clin Cancer Res. 2009;15:5829–39.CrossRefPubMedGoogle Scholar

Copyright information

© The Korean Tissue Engineering and Regenerative Medicine Society and Springer Science+Business Media B.V., part of Springer Nature 2018

Authors and Affiliations

  1. 1.SMG-SNU Boramae Medical CenterSeoulSouth Korea
  2. 2.Research Institute of BiotechnologyMedifab Co, Ltd.SeoulSouth Korea
  3. 3.Department of Orthopedic Surgery, College of MedicineSeoul National UniversitySeoulSouth Korea

Personalised recommendations